Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG545 (Pixatimod) in Advanced Solid Tumours
NCT02042781Phase 1Completed
- Sponsor
- Zucero Therapeutics
- Start
- Jan 2014
- Primary completion
- Jun 2016
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pixatimod in solid tumor (advanced stage), sponsored by Zucero Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2014; status: completed.
02
Drugs
pixatimod
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02042781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042781.